Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Wins Round in Battle to Keep Roche’s EPO Off Market

Executive Summary

Amgen has the edge as its patent battle against Roche goes to trial this week since the federal judge overseeing the dispute found that Roche's anti-anemia drug Mircera infringes a key Amgen patent

You may also be interested in...



“World Series” Trial: Verdict Against Mircera Gives Amgen ESA Market Hold

While Roche is considering whether to appeal a jury verdict that its anti-anemia drug Mircera infringes Amgen's erythropoietin patents covering Epogen and Aranesp, Amgen is likely to retain its dominance over the $6 billion-plus erythropoiesis-stimulating agents market for some time

“World Series” Trial: Verdict Against Mircera Gives Amgen ESA Market Hold

While Roche is considering whether to appeal a jury verdict that its anti-anemia drug Mircera infringes Amgen's erythropoietin patents covering Epogen and Aranesp, Amgen is likely to retain its dominance over the $6 billion-plus erythropoiesis-stimulating agents market for some time

Roche Puts “Mind Towards” Phase III For CETP Inhibitor

Roche is leaning in favor of initiating a Phase III study of its cholesteryl ester transfer protein inhibitor, R1658, after conducting an in-depth analysis of data, evaluating information on Pfizer's failed torcetrapib and consulting experts

Latest News
See All
UsernamePublicRestriction

Register

PS048736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel